Proteomics International Laboratories Limited (ASX: PIQ) came up with performance results of PromarkerD immunoassay kit. The results were presented on November 9, 2018 at the 18th Annual Diabetes Technology meeting held between November 08, and November 10, 2018 at North Bethesda, Marylan. Highly positive results were shown by PromarkerD protein biomarkers. PromarkerD outperformed both the existing diagnostic tests for the measurement of “ACR” (albumin creatinine ratio) urine test “and the measurement of “eGFR”blood test (estimated glomerular filtration rate) .The test were done in order to predict future diabetic kidney disease, with adjusted odds ratio of 1.98 (95%CI 1.31-3.01) versus odds ratio of 1.16 (0.94-1.42) and odds ratio of 0.87 (0.85-0.9), respectively. As per the guidelines issued by the Clinical and Laboratory Standards Institute, the scores were measured using the mass spectrometry platform (LDT) and immunoassay (IVD kit).
The test was performed on 100 patients having type 2 diabetes. Results from these two tests were noted down and data was analysed for the estimating risk of future diabetic kidney disease. The results from these two tests were highly correlated giving the correlation coefficient of 0.989. As per the clinical studies presented in June 2017 at the American Diabetes Association Annual Scientific Sessions and the reports published on September 6, 2017 in the prestigious journal Diabetes Care, PromarkerD successfully predicted 86% of otherwise healthy diabetic patients who suffered from severe chronic kidney disease within a span of four years. Global research house Frost and Sullivan in its report published on March 27, 2017 with title Biomarkers Enabling Diabetes and obesity management has rated PromarkerD as the world’s leading diagnostic test for detecting diabetic kidney disease. PromarkerD protein biomarkers has received patent protection in several major jurisdictions including the USA, Europe, China and Japan.
PromarkerD immunoassay kit uses and immunoassay format are known as vitro diagnostic or IVD. The kit can be used in all pathology labs around the world, subjective to regulatory approvals. Omics Global Solutions, the International partner of Proteomics will be the first to use the new kit. Omics Global solution will use the services through its distributor and the exclusive dialysis service provider, Macrotech Farmaceutica in the Dominican Republic.
While presenting the results of PromarkerD, Managing director of Proteomics International expressed his views on the potentiality of the kit. According to him, Diabetes and diseases associated with it pose a major global health problem which is putting an extra burden on the health sector. PromarkerD can provide a major help in this area and can save the director cost associated with treating the end-stage kidney disease in the US healthcare system up to USD100 billion per year.
The first commercial batch of the PromarkerD immunoassay kit will be ready for the shipment on November 20, 2018, followed by the completion of the production of the key antibody reagents in Puerto Rico and manufacturing of the kit at certified facilities in California. The kit will be used to target new commercialization deals in Japan and India which will further open the door to new avenues of commercialization discussions around the world.
The highly positive data figures of the PromarkerD kit and its wide acceptance definitely signals the power of this platform and the steps and innovations of Proteomics International in this field of predictive testing for global diseases. PIQ made a new 52 week high of $0.38 in early session of November 9, 2018 and closed at the levels of $0.325, up 16%.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.